Personalised mRNA Cancer Vaccine: A New Milestone
Recent results from a large clinical study have shown that a mRNA vaccine designed for each patient’s tumour can markedly improve survival in high‑risk melanoma. The finding signals a possible shift from generic chemotherapy to truly personalised cancer care.
Key Developments
- Phase III INTerpath-001 trial enrolled ~1,100 patients after complete surgical removal of melanoma.
- Patients received standard pembrolizumab alone or together with an individualised vaccine created from the tumour’s genetic profile.
- The combination cut the risk of recurrence by about 49% and distant metastasis by 59% compared with pembrolizumab alone.
- The vaccine works by targeting neoantigens – unique mutations present only in a patient’s cancer cells.
Important Facts
Traditional vaccines prevent infections; these are therapeutic vaccines administered after a disease is diagnosed. After tumour sequencing, AI algorithms select the most immunogenic neoantigens and synthesize mRNA constructs that encode them. When injected, the mRNA is taken up by the body’s cells, which then produce the tumour‑specific proteins and train checkpoint inhibitors and T‑cells to recognise and destroy the cancer.
Earlier waves of cancer treatment included:
- 1970‑80s: chemotherapy – broad‑acting drugs that killed rapidly dividing cells.
- 1990‑2000s: targeted therapy – drugs aimed at specific genetic abnormalities such as HER2 or EGFR.
- Last two decades: immunotherapy – checkpoint inhibitors, CAR‑T cell therapy, and bispecific antibodies.
Exam Relevance
The evolution of cancer care illustrates the interplay of science, technology, and public health policy – a recurring theme in GS 1 (Society & Health) and GS 3 (Science & Technology). Understanding how mRNA vaccines are developed, approved, and scaled can inform questions on health‑care delivery, regulatory frameworks, and indigenous biotech capability.
Key policy considerations include:
- Strengthening genomic sequencing infrastructure in public hospitals.
- Regulating personalised therapies to ensure safety, affordability, and equitable access.
- Promoting public‑private partnerships for rapid vaccine design, leveraging lessons from the COVID‑19 response.
Way Forward
To translate trial success into routine practice, India needs:
- National guidelines for post‑surgical tumour sequencing and rapid vaccine manufacture.
- Capacity building for AI‑driven neoantigen discovery within research institutes.
- Funding mechanisms that subsidise personalised vaccines for economically weaker sections.
- Robust pharmacovigilance to monitor long‑term outcomes of mRNA‑based therapies.
If these steps are taken, personalised mRNA vaccines could become a cornerstone of cancer treatment, echoing the earlier paradigm shift brought by immunotherapy.